

REGIONAL PEDIATRIC PARENTERAL DRUG MONOGRAPH

GENERIC NAME

piperacillin-tazobactam

Effective Date:	May14-2014	CLAS	SIFICATION		OTHER NA	MES	PAGE
Revised Date: Jan 2023		Antibacterial			Tazocin		1 of 2
ADMINISTRA	ATION POLIC	Y:		•			
IV Infusion – May be administered by a nurse MINI-BAG PLUS COMPATIBLE							
IM Injection	- Not recomme	ended					
RECONSTITU	UTION/DILUT	ION/ADN	AINISTRA	TION:			
Available	Combinat	tion	Diluent	Final	Final	Preferred	Alternate
As	Descripti	ion	volume	Volume	Concentration	Diluent Volumes	Bag Size
						Bag Size	C
2.25 gram	Piperacillin 2 g	gram				50 to 100 mL	25 mL
	and		8.4 mL	10 mL			
Viai	Tazobactam 0.2	.25 gram			225 mg/mL		
	Piperacillin 3 g	riperacillin 3 gram nd Sazobactam 0.375		15 mL	(equivalent to	50 to 100 mL	N/A
3.375 gram vial	and				piperacillin 200		
	Tazobactam 0.				mg/mL		
	gram				tazobactam 25		
4.5 gram vial	Piperacillin 4 g	gram			mg/mL)	50 to 100 mL	N/A
	and		16.9 mL	20 mL			
	Tazobactam 0.	5 gram					
To maximize speed o	f reconstitution, loosen	ı powder in th	e vial by lightly	tapping the vi	al prior to reconstitution o	r docking with MINI-BAG P	LUS bag

IV Intermittent:

MINI-BAG PLUS COMPATIBLE Administer over at least 30 minutes

DOSAGE: All Dosages Expressed as Piperacillin Component

Infant, Child: 200 to 300 mg/kg/24 hours divided every 6 to 8 hours (may be divided every 4 hours)

Cystic Fibrosis: 300 to 500 mg/kg/24 hours divided every 4 to 8 hours

Febrile Neutropenia: 240 to 300 mg/kg/24 hours divided every 6 to 8 hours

Renal Impairment: Dosage adjustment required

Hepatic impairment: No dosage adjustment required

Maximum daily dose:18 gramsMaximum concentration:90 mg/mL

STABILITY/COMPATIBILITY:

Stability of reconstituted vial:24 hours at room temperatureStability of Final Admixture:24 hours at room temperatureCompatibility:Compatible with normal saline, D5WIncompatible with Lactated Ringer

Approved by Regional Pharmacy & Therapeutics Committee





REGIONAL PEDIATRIC PARENTERAL DRUG MONOGRAPH

GENERIC NAME

piperacillin-tazobactam

Effective Date: May14-2014	CLASSIFICATION	OTHER NAMES	PAGE
Revised Date: Jan 2023	Antibacterial	Tazobactam	2 of 2

POTENTIAL HAZARDS:

- Hypersensitivity: increased incidence in patients with cystic fibrosis, rash, urticaria, fever
- CV: hypertension, edema
- GI: nausea, vomiting, diarrhea
- Metab: decrease serum potassium (particularly in patients with hepatic disease or with concurrent cytotoxic drugs)
- Neuro: headache or dizziness, agitation, insomnia, seizures
- Renal: increase in serum creatinine or BUN
- Local: thrombophlebitis, pain at injection site
- Other: superinfection, serum-sickness reaction

REOUIRED MONITORING

- Presence of nausea, vomiting and headache action: decrease infusion rate
- Thrombophlebitis (common)
- action: dilute to at least 60 mg/mL, normal saline preferred • For therapy greater than 10 days in duration, check CBC and platelet count at least once weekly

CAUTION

- Patients allergic to cephalosporin antibiotics may also be allergic to penicillin
- Use of high doses in patients with pre-existing seizure disorder
- · Renal impairment: decreased platelet aggregation and prolonged bleeding time

CONTRAINDICATIONS

• Hypersensitivity to penicillin or other beta-lactam antibiotics

ADDITIONAL NOTES:

- If administering aminoglycoside antibiotics (i.e. gentamicin, tobramycin) concurrently, flush IV tubing and catheter with at least 1.5 times the catheter volume "dead space" with normal saline between medications to prevent inactivation and possible precipitation.
- Tazobactam inhibits the enzyme B-lactamase. This extends and enhances the spectrum of activity of piperacillin.
- Piperacillin has a very short half-life (0.5 to 2 hours). Some sources report better outcomes when piperacillintazobactam is infused over 3 to 4 hours.